3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Prostatic Neoplasms
5
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hepatoblastoma
1
Cardiovascular Diseases
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
4
Etoposide
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Sirolimus
2
Paclitaxel
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
tremelimumab
1
ripretinib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
guadecitabine
1
fosaprepitant
1
fludarabine phosphate
1
durvalumab
1
bintrafusp alfa protein, human
1
avelumab
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Simvastatin
×
Genitourinary
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled